ONTX Onconova Therapeutics Inc.
3.69
-0.01 -0%
Previous Close
3.7
Open
3.7
Price To Book
1.93
Market Cap
20937872
Shares
5,674,220
Volume
50,247
Short Ratio
Av. Daily Volume
145,192
NewsSee all news
- Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
- Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
- Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
- Bucks County biopharm firm names new CEO
- Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
SEC filingsSee all SEC filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604968
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604760
- 8-K - Current report 19527660
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19504494
- 8-K - Current report 181212809
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Latest News
- Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
- Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
- Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
- Bucks County biopharm firm names new CEO
- Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
- Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
- Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
- Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
- Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
- Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT
- Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)
- Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences
- Bucks County biopharm firm implements reverse stock split
SEC Filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604968
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604760
- 8-K - Current report 19527660
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19504494
- 8-K - Current report 181212809
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181184927
- 8-K - Current report 181175335
- 8-K - Current report 181121404
- 8-K - Current report 181086110
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181018936